Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 11/20 | 0.49 |
| ▸ | KDR | P35968 | 10/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.49 |
| ▸ | FLT1 | P17948 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695040 | 1.00 | EGFR (0.52) | EGFREPHA2KDRERBB2EPHB4 | |
| SCHEMBL20695049 | 1.00 | EGFR (0.52) | EGFREPHA2KDRERBB2EPHB4 | |
| SCHEMBL20695007 | 0.96 | EGFR (0.48) | EGFREPHA2KDRERBB2EPHB4 | |
| SCHEMBL20695036 | 0.96 | EGFR (0.48) | EGFREPHA2KDRERBB2EPHB4 | |
| SCHEMBL20695062 | 0.96 | EGFR (0.48) | EGFREPHA2KDRERBB2EPHB4 | |
| SCHEMBL22490389 | 0.92 | EGFR (0.49) | EGFREPHA2KDRERBB2EPHB4 | |
| SCHEMBL20695028 | 0.91 | EGFR (0.65) | EGFREPHA2KDRERBB2EPHB4 | |
| SCHEMBL20695014 | 0.91 | EGFR (0.65) | EGFREPHA2KDRERBB2EPHB4 | |
| SCHEMBL20695011 | 0.91 | EGFR (0.65) | EGFREPHA2KDRERBB2EPHB4 | |
| SCHEMBL20695029 | 0.89 | KDR (0.50) | EGFREPHA2KDRERBB2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168067-B2 | Substituted quinazoline compound having blood-brain barrier penetration capability | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-11168067-B2 | Substituted quinazoline compound having blood-brain barrier penetration capability | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| EP-3438107-B1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| EP-3438107-B1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| CN-108069946-B | Substituted quinazoline compounds having the ability to cross the blood brain barrier | 威尚（上海）生物医药有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-3438107-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. (CN) | 2019-02-06 | — | — | EP | disclosed |
| EP-3438107-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. (CN) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | KDR, FLT4, EGFR | EGFR 3/4885EPHA2 496/4885KDR 1/4885 |
| US-11168067-B2 | Substituted quinazoline compound having blood-brain barrier penetration capability | KDR, FLT4, EGFR | EGFR 3/4885EPHA2 496/4885KDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.